A detailed history of Fin Trust Capital Advisors, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 3 shares of MRNA stock, worth $110. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3
Previous 76 96.05%
Holding current value
$110
Previous $9,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$63.64 - $125.14 $4,645 - $9,135
-73 Reduced 96.05%
3 $0
Q2 2024

Jul 24, 2024

BUY
$101.21 - $166.61 $2,732 - $4,498
27 Added 55.1%
76 $9,000
Q4 2023

Feb 13, 2024

SELL
$69.51 - $104.43 $8,688 - $13,053
-125 Reduced 71.84%
49 $4,000
Q3 2023

Oct 24, 2023

BUY
$96.41 - $126.61 $10,701 - $14,053
111 Added 176.19%
174 $17,000
Q3 2022

Oct 20, 2022

SELL
$118.07 - $194.18 $14,758 - $24,272
-125 Reduced 66.49%
63 $8,000
Q2 2022

Jul 26, 2022

BUY
$117.13 - $176.59 $19,443 - $29,313
166 Added 754.55%
188 $31,000
Q1 2022

May 03, 2022

SELL
$126.46 - $235.05 $13,278 - $24,680
-105 Reduced 82.68%
22 $4,000
Q4 2021

Feb 14, 2022

SELL
$225.82 - $368.51 $41,550 - $67,805
-184 Reduced 59.16%
127 $32,000
Q3 2021

Nov 16, 2021

BUY
$221.9 - $484.47 $3,772 - $8,235
17 Added 5.78%
311 $120,000
Q1 2021

May 17, 2021

SELL
$109.18 - $185.98 $10,918 - $18,598
-100 Reduced 25.38%
294 $38,000
Q4 2020

Feb 16, 2021

BUY
$65.74 - $169.86 $12,753 - $32,952
194 Added 97.0%
394 $41,000
Q3 2020

Nov 10, 2020

BUY
$54.34 - $94.85 $2,499 - $4,363
46 Added 29.87%
200 $14,000
Q2 2020

Sep 11, 2020

BUY
$29.67 - $80.0 $4,569 - $12,320
154 New
154 $10,000
Q2 2020

Aug 14, 2020

SELL
$29.67 - $80.0 $4,005 - $10,800
-135 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$17.78 - $31.58 $2,400 - $4,263
135 New
135 $4,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Fin Trust Capital Advisors, LLC Portfolio

Follow Fin Trust Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.